Ratings Oncopeptides AB

Equities

ONCO

SE0009414576

Real-time Estimate Cboe Europe Other stock markets 04:49:42 2024-04-25 am EDT			5-day change	1st Jan Change
3.125 ^SEK	-2.95%		-32.49%	-59.99%

Apr. 15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI
Apr. 04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
With an enterprise value anticipated at 5.4 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ONCOPEPTIDES AB	-59.99%	29.2M	C+
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B	B+
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B	B+
ARGENX SE	+1.08%	22.2B	B
BIONTECH SE	-16.53%	21.23B	B+
GENMAB A/S	-8.56%	18.33B	A-
WUXI APPTEC CO., LTD.	-42.33%	16.35B	A-
BEIGENE, LTD.	-20.09%	15.06B	B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B	C+
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes